Evaluation of contrast sensitivity in non-high-risk proliferative diabetic retinopathy treated with panretinal photocoagulation with and without intravitreal injections of ranibizumab

Rentiya, Zubir; Ferraz, Daniel; Hutnik, Robert; Bae, Junun; Machado, Cleide Guimarães; Mucciolli, Cristina; Motta, Augusto; Ribeiro, Lucas Zago; Guan, Zeyu; Preti, Rony Carlos; Takahashi, Walter Yukihiko

doi:10.5935/0004-2749.20220006

Cited by 3 publications

(2 citation statements)

References 13 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Combination therapy with PRP and ranibizumab showed a potential benefit of preserving contrast sensitivity compared to PRP monotherapy in patients without HR-PDR. [ 34 ] The present study demonstrated that PRP + aVEGF was superior to PRP monotherapy in treating HR-PDR patients. Although there were no significant differences in the change of BCVA and FLA as well as the risks of vitreous hemorrhage and other complications between the 2 groups, the change of CMT and rate of undergoing vitrectomy were markedly decreased in PRP + aVEGF group.…”

Section: Discussionmentioning

confidence: 66%

Efficacy and safety of pan retinal photocoagulation combined with intravitreal anti-VEGF agents for high-risk proliferative diabetic retinopathy: A systematic review and meta-analysis

Fu,

Huang,

Wan

et al. 2023

Medicine

View full text Add to dashboard Cite

Background: High-risk proliferative diabetic retinopathy (HR-PDR) is the advanced stage of diabetic retinopathy progression with poor prior treatment efficacy and high rates of blindness. This meta-analysis aims to compare the efficacy and safety of pan retinal photocoagulation (PRP) combined with intravitreal anti-vascular endothelial growth factor (aVEGF) (PRP + aVEGF) versus PRP monotherapy in HR-PDR patients. Methods: A thorough search was performed through PubMed, Web of Science, EMBASE, and the Cochran Library from inception to December 18, 2022. Outcome measures included change in central macular thickness, best-corrected visual acuity, fluorescein angiography, incidence of undergoing vitrectomy, and adverse events during the follow-up period. Results: Eight studies (6 randomized controlled trials and 2 retrospective studies) with 375 eyes were included in this meta-analysis. There were no obvious differences in the changes of best-corrected visual acuity and fluorescein angiography between the PRP + aVEGF and PRP monotherapy groups. However, PRP + aVEGF group had a significant reduction in the change of central macula thickness (standard mean deviations = −1.44, 95%CI = −2.55 to −0.32, P = .01) and the rate of undergoing vitrectomy (odds ratio = 0.20, 95%CI = 0.05–0.83, P = .01). Additionally, the risks of vitreous hemorrhage and other complications were not significantly different between the 2 groups. Conclusion subsections: Our meta-analysis indicated that PRP + aVEGF might have potential benefits in the treatment of HR-PDR patients. However, given several limitations of this study, more research is needed to confirm our findings.

show abstract

Section: Discussionmentioning

confidence: 66%

Efficacy and safety of pan retinal photocoagulation combined with intravitreal anti-VEGF agents for high-risk proliferative diabetic retinopathy: A systematic review and meta-analysis

Fu,

Huang,

Wan

et al. 2023

Medicine

View full text Add to dashboard Cite

show abstract

“…A second trial demonstrated that the use of intravitreal bevacizumab as pre-treatment 15 days before PRP resulted in significant improvement in visual acuity and regression of neovascularization at 30 days compared to PRP alone [ 55 ]. In a third trial, a single dose of adjunctive intravitreal ranibizumab with PRP was associated with improved low-frequency contrast sensitivity thresholds at one, three, and six months compared with PRP alone [ 56 ].…”

Section: Anti-vegf As An Adjunct To Prp For Pdrmentioning

confidence: 99%

Update on the Management of Diabetic Retinopathy: Anti-VEGF Agents for the Prevention of Complications and Progression of Nonproliferative and Proliferative Retinopathy

Bahr

Bakri

2023

Life

View full text Add to dashboard Cite

Diabetic retinopathy (DR) is a microvascular disease caused by poorly controlled blood glucose, and it is a leading cause of vision loss in people with diabetes. In this review we discuss the current management of DR with particular focus on the use of intraocular anti-vascular endothelial growth factor (anti-VEGF) agents. Intraocular anti-VEGF agents were first studied in the 1990s, and now several of these agents are either FDA approved or used off-label as first-line treatments for DR. Recent evidence shows that anti-VEGF agents can halt the progression of markers of DR severity, reduce the risk of DR worsening, and reduce the onset of new macular edema. These significant benefits have been demonstrated in patients with proliferative DR and the milder nonproliferative DR (NPDR). A wealth of evidence from recent trials and meta-analyses has detailed the intraoperative and postoperative benefits of adjunctive anti-VEGF therapy prior to pars plana vitrectomy (PPV) for proliferative DR with vitreous hemorrhage. In this review, we also discuss literature comparing various anti-VEGF injection regimens including monthly, quarterly, as-needed, and treat and extend protocols. Combination protocols with panretinal photocoagulation (PRP) or PPV are also discussed. Current evidence suggests that anti-VEGF therapies are effective therapy for NPDR and PDR and may also provide significant benefits when used adjunctively with other DR treatment modalities such as PRP or PPV.

show abstract

Efficacy of ranibizumab with laser in the treatment of diabetic retinopathy compare with laser monotherapy: A systematic review and meta-analysis

Huang,

Liang,

Liu

et al. 2024

Technology and Health Care

View full text Add to dashboard Cite

Background Diabetic retinopathy (DR) is one of the serious complications of diabetes mellitus. Laser therapy is the traditional treatment for DR, and the role of vitreous injection of ranibizumab in DR requires evaluation. This meta-analysis aimed to compare the efficacy of ranibizumab combined with laser versus laser monotherapy in treating diabetic retinopathy. Method We searched PubMed, Scopus, Web of Science, Embase, China Biology Medicine Disc (CBM), China National Knowledge Infrastructure (CNKI), and Wanfang databases, from their inception to October 2024. Randomized controlled trials (RCTs) that compared the effectiveness of ranibizumab combined with laser versus laser monotherapy in the treatment of diabetic retinopathy were searched. We used the Cochrane Collaboration tool to evaluate the risk of bias. Results Our analysis included 18 studies. The improvement time for retinal edema in the ranibizumab combined with the laser group was significantly shorter than that in the laser monotherapy group ( P < 0.05). The time to absorb fundus hemorrhage in the ranibizumab combined with the laser group was significantly shorter than that in the laser monotherapy group ( P < 0.05). The absorption time of fundus exudation in the ranibizumab combined with the laser group was significantly lower than that of the laser monotherapy group ( P < 0.05). The rate of improvement in vision in the ranibizumab combined with the laser group was significantly higher than that of the laser monotherapy group ( P < 0.05). There were no significant differences in the incidence of adverse reactions ( P > 0.05) and retinal thickness in the macula ( P > 0.05) between ranibizumab combined with the laser group and the laser monotherapy group. onclusion The combination of ranibizumab and laser for diabetic retinopathy is more effective than laser monotherapy.

show abstract

Evaluation of contrast sensitivity in non-high-risk proliferative diabetic retinopathy treated with panretinal photocoagulation with and without intravitreal injections of ranibizumab

Cited by 3 publications

References 13 publications

Efficacy and safety of pan retinal photocoagulation combined with intravitreal anti-VEGF agents for high-risk proliferative diabetic retinopathy: A systematic review and meta-analysis

Efficacy and safety of pan retinal photocoagulation combined with intravitreal anti-VEGF agents for high-risk proliferative diabetic retinopathy: A systematic review and meta-analysis

Update on the Management of Diabetic Retinopathy: Anti-VEGF Agents for the Prevention of Complications and Progression of Nonproliferative and Proliferative Retinopathy

Efficacy of ranibizumab with laser in the treatment of diabetic retinopathy compare with laser monotherapy: A systematic review and meta-analysis

Contact Info

Product

Resources

About